Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance)

Sikov William M.; Berry Donald A.; Perou Charles M.; Singh Baljit; Cirrincione Constance T.; Tolaney Sara M.; Kuzma Charles S.; Pluard Timothy J.; Somlo George; Port Elisa R.; Golshan Mehra; Bellon Jennifer R.; Collyar Deborah; Hahn Olwen M.; Carey Lisa A.; Hudis Clifford A.; Winer Eric P.

首页> 外文期刊>Journal of Clinical Oncology >Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance)

【24h】

Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance)

机译：在每周一次的紫杉醇新辅助治疗中加用卡铂和/或贝伐单抗后加剂量密集的阿霉素和环磷酰胺对II至III期三阴性乳腺癌病理完全缓解率的影响：CALGB 40603（联盟）

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Purpose

机译：目的

著录项

来源
《Journal of Clinical Oncology》 |2015年第1期|共9页
作者
Sikov William M.; Berry Donald A.; Perou Charles M.; Singh Baljit; Cirrincione Constance T.; Tolaney Sara M.; Kuzma Charles S.; Pluard Timothy J.; Somlo George; Port Elisa R.; Golshan Mehra; Bellon Jennifer R.; Collyar Deborah; Hahn Olwen M.; Carey Lisa A.; Hudis Clifford A.; Winer Eric P.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance) [J] . Sikov William M., Berry Donald A., Perou Charles M., Journal of Clinical Oncology . 2015,第1期

机译：在每周一次的紫杉醇新辅助治疗中加用卡铂和/或贝伐单抗后加剂量密集的阿霉素和环磷酰胺对II至III期三阴性乳腺癌病理完全缓解率的影响：CALGB 40603（联盟）
2. SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer [J] . Nahleh Z. A., Barlow W. E., Hayes D. F., Breast cancer research and treatment. . 2016,第3期

机译：SWOG S0800（NCI CDR0000636131）：将贝伐单抗与剂量密集的阿霉素和环磷酰胺一起添加到新辅助的nab-紫杉醇中，可改善炎性或局部晚期乳腺癌的病理完全缓解率（pCR）
3. Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84): A randomised phase III trial [J] . Schneeweiss Andreas, Moebus Volker, Tesch Hans, European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2019,第期

机译：激烈剂量 - 致密的Epirubicin，紫杉醇，环磷酰胺与每周紫杉醇，脂质体Doxorubicin（加上三重阴性乳腺癌中的Carboplatin）用于Neoadjuvant治疗高危早期乳腺癌（Geparocto-GBG 84）：随机期III试验
4. Prediction of Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer Using Deep Learning with Integrative Imaging, Molecular and Demographic Data [C] . Hongyi Duanmu, Pauline Boning Huang, Srinidhi Brahmavar, International Conference on Medical Image Computing and Computer-Assisted Intervention . 2020

机译：利用综合成像，分子和人口统计数据预测对乳腺癌新辅助化疗的病理完全反应
5. Using Preoperative Mri-guided Biopsies to Predict Pathologic Complete Response after Neoadjuvant Chemotherapy in Breast Cancer [D] . Kim, Jiyoon. 2019

机译：在乳腺癌新辅助化疗后使用术前Mri引导的活检来预测病理完全缓解
6. Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance) [O] . William M. Sikov, Donald A. Berry, Charles M. Perou, -1

机译：在每周一次的紫杉醇新辅助治疗中加用卡铂和/或贝伐单抗再加剂量密集的阿霉素和环磷酰胺对II至III期三阴性乳腺癌病理完全缓解率的影响：CALGB 40603（联盟）
7. SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer [O] . Z. A. Nahleh, W. E. Barlow, D. F. Hayes, 2016

机译：SWOG S0800（NCI CDR0000636131）：将贝伐单抗与剂量密集的阿霉素和环磷酰胺一起添加到新辅助的nab-紫杉醇中可改善炎症性或局部晚期乳腺癌的病理完全缓解率

Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance)

摘要

著录项

相似文献

相关主题

期刊订阅